Is Stereotaxis, Inc. overvalued or undervalued?

As of 9 May 2019, the valuation grade for Stereotaxis, Inc. moved from fair to risky, indicating a deterioration in its investment appeal. The company is overvalued, as evidenced by its high Price to Book Value of 23.67 and negative EV to EBIT and EV to EBITDA ratios of -7.08 and -7.42, respectively. Additionally, the Return on Equity (ROE) is alarmingly low at -310.19%, reflecting significant financial distress.
In comparison to its peers, Stereotaxis, Inc. exhibits a notably worse valuation profile; for instance, Bioventus, Inc. has a P/E ratio of 72.81, while Semler Scientific, Inc. is considered attractive with a P/E ratio of 32.26. The stock has shown mixed performance against the S&P 500, with a year-to-date return of 22.81% compared to the index's 12.22%, but a disappointing 5-year return of -25.73% versus the S&P 500's impressive 96.61%.